Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation | Zendy

Johan Maertens | Zendy; Catherine Cordonnier | Zendy; Péter Jaksch | Zendy; Xavier Poiré | Zendy; Marc E. Uknis | Zendy; Jingyang Wu | Zendy; Anna Wijatyk | Zendy; Faouzi Saliba | Zendy; Oliver Witzke | Zendy; Stephen Villano | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Maribavir for Preemptive Treatment of Cytomegalovirus Reactivation

Author(s) -

Johan Maertens,

Catherine Cordonnier,

Péter Jaksch,

Xavier Poiré,

Marc E. Uknis,

Jingyang Wu,

Anna Wijatyk,

Faouzi Saliba,

Oliver Witzke,

Stephen Villano

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1714656

Subject(s) - medicine , valganciclovir , confidence interval , ganciclovir , randomization , cytomegalovirus , clinical endpoint , transplantation , surgery , randomized controlled trial , gastroenterology , human cytomegalovirus , immunology , herpesviridae , viral disease , virus

Maribavir is a benzimidazole riboside with activity against cytomegalovirus (CMV). The safety and efficacy of maribavir for preemptive treatment of CMV infection in transplant recipients is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research